A
Arnaldo Lopes Colombo
Researcher at Federal University of São Paulo
Publications - 298
Citations - 18359
Arnaldo Lopes Colombo is an academic researcher from Federal University of São Paulo. The author has contributed to research in topics: Fluconazole & Candida albicans. The author has an hindex of 68, co-authored 279 publications receiving 15284 citations. Previous affiliations of Arnaldo Lopes Colombo include University of Toronto & Hospital General Universitario Gregorio Marañón.
Papers
More filters
Journal ArticleDOI
Comparison of caspofungin and amphotericin B for invasive candidiasis.
Jorge Mora-Duarte,Robert F. Betts,Coleman Rotstein,Arnaldo Lopes Colombo,Luis Thompson-Moya,Juanita M Smietana,Robert J. Lupinacci,Carole A. Sable,Nicholas A. Kartsonis,John R. Perfect +9 more
TL;DR: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Journal ArticleDOI
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Shawn R. Lockhart,Kizee A. Etienne,Snigdha Vallabhaneni,Joveria Farooqi,Anuradha Chowdhary,Nelesh P. Govender,Arnaldo Lopes Colombo,Belinda Calvo,Christina A. Cuomo,Christopher A. Desjardins,Elizabeth L. Berkow,Mariana Castanheira,Rindidzani E. Magobo,Kauser Jabeen,Rana Jawad Asghar,Jacques F. Meis,Brendan R Jackson,Tom Chiller,Anastasia P. Litvintseva +18 more
TL;DR: Candida auris is an emerging healthcare-associated pathogen associated with high mortality, and WGS analysis suggests nearly simultaneous, and recent, independent emergence of different clonal populations on 3 continents.
Journal ArticleDOI
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
Oliver A. Cornely,Ana Alastruey-Izquierdo,Dorothee Arenz,Sharon C.-A. Chen,Eric Dannaoui,Bruno Hochhegger,Bruno Hochhegger,Martin Hoenigl,Martin Hoenigl,Henrik Jeldtoft Jensen,Katrien Lagrou,Russell E. Lewis,Sibylle C. Mellinghoff,Mervyn Mer,Zoi D. Pana,Danila Seidel,Donald C. Sheppard,Roger Wahba,Murat Akova,Alexandre Alanio,Abdullah M. S. Al-Hatmi,Sevtap Arikan-Akdagli,Hamid Badali,Ronen Ben-Ami,Alexandro Bonifaz,Stéphane Bretagne,Elio Castagnola,Methee Chayakulkeeree,Arnaldo Lopes Colombo,Dora E. Corzo-Leon,Lubos Drgona,Andreas H. Groll,Jesús Guinea,Jesús Guinea,Claus Peter Heussel,Ashraf S. Ibrahim,Souha S. Kanj,Nikolay Klimko,Michaela Lackner,Frédéric Lamoth,Fanny Lanternier,Cornelia Lass-Floerl,Dong-Gun Lee,Thomas Lehrnbecher,Badre E. Lmimouni,Mihai Mares,Georg Maschmeyer,Jacques F. Meis,Joseph Meletiadis,Joseph Meletiadis,C. Orla Morrissey,Marcio Nucci,Rita O. Oladele,Livio Pagano,Alessandro C. Pasqualotto,Atul Patel,Zdenek Racil,Malcolm Richardson,Emmanuel Roilides,Markus Ruhnke,Seyedmojtaba Seyedmousavi,Seyedmojtaba Seyedmousavi,Neeraj Sidharthan,Nina Singh,Janos Sinko,Anna Skiada,Monica A. Slavin,Monica A. Slavin,Rajeev Soman,Brad Spellberg,William J. Steinbach,Ban Hock Tan,Andrew J. Ullmann,Joerg J. Vehreschild,Maria J G T Vehreschild,Thomas J. Walsh,P. Lewis White,Nathan P. Wiederhold,Theoklis E. Zaoutis,Arunaloke Chakrabarti +79 more
TL;DR: Management of mucormycosis depends on recognising disease patterns and on early diagnosis, and limited availability of contemporary treatments burdens patients in low and middle income settings.
Journal ArticleDOI
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
Philipp Koehler,Matteo Bassetti,Arunaloke Chakrabarti,Sharon C.-A. Chen,Sharon C.-A. Chen,Arnaldo Lopes Colombo,Martin Hoenigl,Martin Hoenigl,Nikolay Klimko,Cornelia Lass-Flörl,Rita O. Oladele,Donald C. Vinh,Li Ping Zhu,Boris Böll,Roger J. M. Brüggemann,Jean-Pierre Gangneux,John R. Perfect,Thomas F. Patterson,Thomas F. Patterson,Thorsten Persigehl,Jacques F. Meis,Jacques F. Meis,Luis Ostrosky-Zeichner,P. Lewis White,Paul E. Verweij,Paul E. Verweij,Oliver A. Cornely +26 more
TL;DR: It is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty, and recommended first-line therapy is either voriconazole or isavuconazole, while azole resistance is a concern.
Journal ArticleDOI
Epidemiology of Candidemia in Brazil: a Nationwide Sentinel Surveillance of Candidemia in Eleven Medical Centers
Arnaldo Lopes Colombo,Marcio Nucci,Benjamin J. Park,Simone A. Nouér,Beth A. Arthington-Skaggs,Daniel Archimedes da Matta,David W. Warnock,Juliette Morgan +7 more
TL;DR: Antifungal resistance was rare, but correlation between fluconazole and voriconazole MICs suggests cross-resistance may occur, and shows the substantial morbidity and mortality of candidemia in Brazil.